Sahar F. Bannoura

Also affiliated with The Barbara Ann Karmanos Cancer Institute, University of Michigan–Dearborn

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers”.

Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0251

N/A

0.533DataRank · unranked

15 citations

Misako Nagasaka, Amro Aboukameel, Osama Alkhalili, Md. Hafiz Uddin, Sahar F. Bannoura +15 more

Connecting the Human Microbiome and Pancreatic Cancer

Cancer and Metastasis Reviews(2022)10.1007/s10555-022-10022-w

N/A

0DataRank · unranked

31 citations

Md. Hafiz Uddin, Sahar F. Bannoura, Husain Yar Khan, Yousef Mzannar, Yiwei Li +8 more

Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy

Advances in Radiation Oncology(2022)10.1016/j.adro.2022.101122

N/A

0DataRank · unranked

20 citations

Mandana Kamgar, Amro Aboukameel, Sahar F. Bannoura, Brian Y. Chung, Yiwei Li +7 more

Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.26.477874

N/A

0DataRank · unranked

1 citations

Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton +13 more

Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer model

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.08.481108

N/A

0DataRank · unranked

0 citations

Amro Aboukameel, Yiwei Li, Husain Yar Khan, Rachel Sexton, Sahar F. Bannoura +11 more

Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model

Clinical and Translational Medicine(2023)10.1002/ctm2.1513

N/A

0DataRank · unranked

17 citations

Mohammad Najeeb Al‐Hallak, Husain Yar Khan, Amro Aboukameel, Yiwei Li, Sahar F. Bannoura +14 more

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.27.534309

N/A

0DataRank · unranked

3 citations

Misako Nagasaka, Amro Aboukameel, Osama Alkhalili, Md. Hafiz Uddin, Sahar F. Bannoura +15 more

Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.18.572102

N/A

0DataRank · unranked

2 citations

Amro Aboukameel, Husain Yar Khan, Md. Hafiz Uddin, Hyejeong Jang, Eliza W. Beal +8 more

Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers

(2023)10.1158/2767-9764.c.6550541

N/A

0DataRank · unranked

0 citations

Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton +13 more

RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth

Cancer Letters(2024)10.1016/j.canlet.2024.217275

N/A

0DataRank · unranked

6 citations

Amro Aboukameel, Husain Yar Khan, Md. Hafiz Uddin, Hyejeong Jang, Eliza W. Beal +13 more

Targeting guanine nucleotide exchange factors for novel cancer drug discovery

Expert Opinion on Drug Discovery(2024)10.1080/17460441.2024.2368242

N/A

0DataRank · unranked

8 citations

Husain Yar Khan, Md. Hafiz Uddin, Ramzi M. Mohammad, Boris Pasche, Asfar S. Azmi +1 more

XPO1 inhibition as a clinically viable strategy to enhance durability of response to KRAS G12D inhibitor in pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.4_suppl.736

N/A

0DataRank · unranked

0 citations

Husain Yar Khan, Amro Aboukameel, Sahar F. Bannoura, Khalil Choucair, Eliza W. Beal +9 more

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.11.21.689857

N/A

0DataRank · unranked

0 citations

Mohammed Najeeb Al Hallak, Amro Aboukameel, Sahar F. Bannoura, Md. Hafiz Uddin, Adeeb A. Aboukameel +27 more

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Frontiers in Oncology(2022)10.3389/fonc.2022.1013902

N/A

0DataRank · unranked

110 citations

Husain Yar Khan, Asfar S. Azmi, Sahar F. Bannoura

Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.64898/2025.12.07.692731

N/A

0DataRank · unranked

0 citations

Zaid Mahdi, Irfana Muqbil, Brendon R Herring, Rose J. Bart, Husain Yar Khan +26 more